about
Epidemiology of otitis media in children from developing countries: A systematic reviewSafety assessment of adjuvanted vaccines: Methodological considerationsEfficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trialSafety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life.Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.Epidemiology of community-acquired pneumonia and implications for vaccination of children living in developing and newly industrialized countries: A systematic literature review.Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian Infants: a randomised trial.Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial.Correction: Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial.Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus GastroenteritisSafety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean childrenEfficacy of the Human Rotavirus Vaccine RIX4414 in Malnourished ChildrenEvaluación del impacto económico de la vacuna antirrotavírica en Venezuela
P50
Q26744794-39D8C151-2EE7-4160-AB2E-8D7AEA2945E1Q27013956-5EBE42DB-F7CF-495B-81C1-4062968194F7Q33848675-C1D05E4A-00EB-43BE-B0C1-35A4A7849281Q34033855-3911FBDB-623C-4E75-948B-D655A2E67243Q34082225-FD700340-D166-4DB6-8535-82517D84EF44Q36256464-4BB4F759-D25F-4DA3-AA4E-603CE48F7EB3Q37264943-AAECC033-6F65-42B1-8056-C04F5F73A55EQ38434329-FCBAB4E0-B47E-4D81-8E53-E78F1F288458Q38829068-9C768272-14EC-48AB-862F-60C3AEAC198DQ42396149-B50F6E39-E153-4DDA-833F-FE5835D0DB77Q54644701-07D65096-44F5-4B90-B808-96F882538644Q56995254-81B3E53D-8DD3-4D38-B0E8-32F4B50DB206Q59245323-692B0533-0012-4C87-AFC5-097B28384EECQ59245325-68BDC2F5-BA91-4714-8626-5D6A2898EE93Q59245328-D6F49F82-4B09-4A9B-B8D1-DFD3C73324C9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Juan Pablo Yarzabal
@ast
Juan Pablo Yarzabal
@en
Juan Pablo Yarzabal
@es
Juan Pablo Yarzabal
@nl
type
label
Juan Pablo Yarzabal
@ast
Juan Pablo Yarzabal
@en
Juan Pablo Yarzabal
@es
Juan Pablo Yarzabal
@nl
prefLabel
Juan Pablo Yarzabal
@ast
Juan Pablo Yarzabal
@en
Juan Pablo Yarzabal
@es
Juan Pablo Yarzabal
@nl
P106
P21
P31
P496
0000-0002-6490-2084